• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Meropenem-vaborbactam non-inferior to piperacillin-tazobactam for complicated urinary tract infections: The TANGO I trial

byQasim HussainiandDaniel Fisher
March 2, 2018
in Emergency, Infectious Disease, Nephrology, Public Health, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, meropenem-vaborbactam was found to be non-inferior to piperacillin-tazobactam for treating complicated urinary tract infections (UTIs).

2. The rate of adverse events were similar between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: As carbapenemases become more prevalent among organisms that cause complicated Urinary Tract Infections (UTIs), the need for antibiotic therapies that cover these organisms also becomes increasingly important. Vaborbactam, a cyclic boronic acid-based beta-lactamase inhibitor, coupled to meropenum is an emerging antibacterial strategy against these organisms, but it is unclear if this regimen is as effective as current therapies. In this randomized controlled trial, meropenum-vaborbactim was found to be non-inferior to piperacillin-tazobactam in treating patients with complicated UTIs. In addition, the rate of adverse effects was found to be similar between groups.

Overall, this study does suggest that vaborbactam-meropenum is a suitable alternative to piperacillin-tazobactam for complicated UTIs, but it remains unclear if this is a suitable strategy against carbapenemase-resistant bacterial infections. Though the authors point out that studying these resistant infections would be difficult because piperacillin-tazobactam would not be an ethical control, a study evaluating vaborbactam-meropenum against these resistant pathogens would be essential to differentiate this treatment from others in terms of clinical usefulness.

Click to read the study, published in JAMA

Relevant Reading: Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence

RELATED REPORTS

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

#VisualAbstract: Shorter antibiotic course non-inferior to longer course for pediatric community-acquired pneumonia

Virtual pediatric acute care visits within the medical home are safe and acceptable to parents

In-Depth [randomized control trial]: The Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO I) study is a phase 3, multicenter, randomized, double-blind trial that enrolled 545 (93% completion rate) adults with complicated UTI from Nov 2014 to April 2016 in 60 sites across 17 countries. Eligible patients were randomized 1:1 using a computer to receive meropenam-vaborbactam (2g/2g over 3 hours; n = 274) or piperacillin-tazobactam (4g/0.5g over 30 minutes; n = 276) every 8 hours. Once a patient had successfully finished 15 or more doses, they could be switched to oral levofloxacin if they met criteria for improvement, to complete 10 days total treatment (intravenous + oral). Clinical outcome assessment was performed on day 3 of therapy, end of intravenous treatment, end of total treatment, and at 7 and 14-days after end of treatment. The primary endpoint was overall success (clinical cure or improvement and microbial eradication) at the end of intravenous treatment. European Medicines Agency (EMA) criteria was used to check for microbial eradication. Overall, success occurred in 189 of 192 (98.2%) patients on meropenem-vaborbactam vs 171 of 182 (94.0%) (difference 4.5%; CI95 0.7% to 9.1%; p < 0.001 for noninferiority). Microbial eradiaction occurred in 128 of 192 (66.7%) with meropenam-vaborbactam vs 105 of 182 (57.7%) with piperacillin-tazobactam (difference 5.9%; CI95 -4.2 to 16.0%]; p < 0.001 for noninferiority). The rate of adverse side effects were similar in each group.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibioticsurinary tract infection (UTI)
Previous Post

Varicose veins associated with higher risk of deep vein thromboses, pulmonary embolisms, and peripheral arterial disease

Next Post

Early diagnosis of HIV infection through analysis of oral fluid [Pre-Clinical]

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
#VisualAbstract: Intensive blood pressure control post-endovascular thrombectomy after acute ischemic stroke linked with worse clinical outcomes
StudyGraphics

#VisualAbstract: Shorter antibiotic course non-inferior to longer course for pediatric community-acquired pneumonia

November 25, 2022
AAP recommends telemedicine to improve access to care
Emergency

Virtual pediatric acute care visits within the medical home are safe and acceptable to parents

November 25, 2022
#VisualAbstract: Cefepime and Enmetazobactam in treatment of urinary tract infection or acute pyelonephritis was more effective than Piperacillin and Tazobactam
StudyGraphics

#VisualAbstract: Cefepime and Enmetazobactam in treatment of urinary tract infection or acute pyelonephritis was more effective than Piperacillin and Tazobactam

October 6, 2022
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

Early diagnosis of HIV infection through analysis of oral fluid [Pre-Clinical]

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Opioid-related pediatric ICU admissions on the rise over past decade

Adjunctive glucocorticoid therapy does not lower mortality in septic shock

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options